M. Ait Lachguer1, A. Mokhtari2, R. Obelahcen4, I. Attifi4, M. Laurentie3 and A. El Hraiki4
1Office National de Sécurité Sanitaire des Aliments, Division de Pharmacie et des Intrants Vétérinaires,
Cité Yakoub El Mansour, Rabat, Morocco
2Laboratoire de génétique et Biométrie, Faculté des Sciences, Université Ibn Tofail, Kénitra, Morocco
3ANSES- Fougères, LERMVD, Unité pharmacocinétique-pharmacodynamique, Fougères Cedex, France
4Département des Sciences Biologiques et Pharmaceutiques Vétérinaires- Institut
Agronomique et Vétérinaire Hassan II, Rabat, Morocco
ABSTRACT
The pharmacokinetic disposition of marbofloxacin and danofloxacin was studied in camels following a high dosage administration as a single-dose (one shot) in a two-period crossover studies. Marbofloxacin was administred by intramuscular and intravenous routes @ 8mg/kg body weight. Danofloxacin was administred by sub-cutaneous and intravenous routes @ 6mg/kg body weight. Concentrations of both fluoroquinolones were measured by high-performance liquid chromatography and the data were subjected to kinetics analysis. The plasma disposition of marbofloxacin was best described by a tri-compartmental for intravenous and a bicompartmental open model with first-order for intramuscular dosing. The Peak plasma concentration (Cmax) of 39.80 ± 11,29 mg/l was reached at (Tmax) 1,16 ± 0,460 h after intamuscular administration. The elimination half-life (t1/2 β) and area under curve of concentration (AUC) were 11.97 ± 3.84 h and 320.65 ± 67.93 mg h/l, respectively. Danofloxacin achieved maximum plasma concentration (Cmax) after sub-cutaneous administration of 27.61 ± 5.00 mg /l at (Tmax) 2.54 ± 1.51h. The distribution half-life (t1/2 β) value of 33.77 ± 32.68 h was obtained for danofloxacin. These data were used together with in vivo pharmacokinetic parameters; Cmax and AUC to determine the surrogate markers of antimicrobial activity; Cmax/MIC and AUC/MIC. Taking into account the values obtained for these markers, it was concluded that an intramuscular dose of 8 mg/kg of marbofloxacin and a sub-cutaneous dose of 6mg/kg of danofloxacin could be adequate for the treatment of infectious diseases caused by high susceptible bacteria such Mannheimia haemolytica and Pasteurella multocida in camels.
Key words: Camels, danofloxacin, fluoroquinolones, marbofloxacin, pharmacokinetic
Home